Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 264

1.

Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.

Zuijdwijk MD, Vogel WV, Corstens FH, Oyen WJ.

Nucl Med Commun. 2008 Jul;29(7):636-41. doi: 10.1097/MNM.0b013e3282f813e1.

PMID:
18528186
2.

Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET.

Visser EP, Philippens ME, Kienhorst L, Kaanders JH, Corstens FH, de Geus-Oei LF, Oyen WJ.

J Nucl Med. 2008 Jun;49(6):892-8. doi: 10.2967/jnumed.107.049585. Epub 2008 May 15.

3.

Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer.

de Geus-Oei LF, van Laarhoven HW, Visser EP, Hermsen R, van Hoorn BA, Kamm YJ, Krabbe PF, Corstens FH, Punt CJ, Oyen WJ.

Ann Oncol. 2008 Feb;19(2):348-52. Epub 2007 Oct 24.

PMID:
17962202
4.

Development and application of peptide-based radiopharmaceuticals.

Dijkgraaf I, Boerman OC, Oyen WJ, Corstens FH, Gotthardt M.

Anticancer Agents Med Chem. 2007 Sep;7(5):543-51. Review.

PMID:
17896914
5.

Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review.

de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ.

Cancer. 2007 Oct 15;110(8):1654-64. Review.

6.

Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer.

de Geus-Oei LF, van der Heijden HF, Visser EP, Hermsen R, van Hoorn BA, Timmer-Bonte JN, Willemsen AT, Pruim J, Corstens FH, Krabbe PF, Oyen WJ.

J Nucl Med. 2007 Oct;48(10):1592-8. Epub 2007 Sep 14.

7.

PET imaging of infection with a HYNIC-conjugated LTB4 antagonist labeled with F-18 via hydrazone formation.

Rennen HJ, Laverman P, van Eerd JE, Oyen WJ, Corstens FH, Boerman OC.

Nucl Med Biol. 2007 Aug;34(6):691-5. Epub 2007 Jul 5.

PMID:
17707809
8.

Scintigraphy with 99mTc-labeled heat-altered erythrocytes in diagnosing hyposplenia: prospective comparison to 99mTc-labeled colloids and colour-coded duplex ultrasonography.

Gotthardt M, Bröker S, Schlieck A, Bauhofer A, Herbst B, Béhé M, Corstens FH, Behr TM, Görg C.

Nuklearmedizin. 2007;46(4):135-40.

PMID:
17690791
9.

Imaging of infectious diseases using [18F] fluorodeoxyglucose PET.

Bleeker-Rovers CP, Vos FJ, Corstens FH, Oyen WJ.

Q J Nucl Med Mol Imaging. 2008 Mar;52(1):17-29. Review.

PMID:
17657204
10.

Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations.

van Dalen JA, Vogel WV, Corstens FH, Oyen WJ.

Cancer Imaging. 2007 May 28;7:77-83. Review.

11.

Evaluation of image registration in PET/CT of the liver and recommendations for optimized imaging.

Vogel WV, van Dalen JA, Wiering B, Huisman H, Corstens FH, Ruers TJ, Oyen WJ.

J Nucl Med. 2007 Jun;48(6):910-9. Epub 2007 May 15.

12.

Radionuclide therapy of cancer with radiolabeled antibodies.

Boerman OC, Koppe MJ, Postema EJ, Corstens FH, Oyen WJ.

Anticancer Agents Med Chem. 2007 May;7(3):335-43. Review.

PMID:
17504159
13.

Impact of Ge-68/Ga-68-based versus CT-based attenuation correction on PET.

van Dalen JA, Visser EP, Vogel WV, Corstens FH, Oyen WJ.

Med Phys. 2007 Mar;34(3):889-97.

PMID:
17441234
14.

Synthesis of DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes.

Dijkgraaf I, Rijnders AY, Soede A, Dechesne AC, van Esse GW, Brouwer AJ, Corstens FH, Boerman OC, Rijkers DT, Liskamp RM.

Org Biomol Chem. 2007 Mar 21;5(6):935-44. Epub 2007 Jan 29.

PMID:
17340009
15.

99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation.

Bleeker-Rovers CP, Rennen HJ, Boerman OC, Wymenga AB, Visser EP, Bakker JH, van der Meer JW, Corstens FH, Oyen WJ.

J Nucl Med. 2007 Mar;48(3):337-43.

16.

Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide.

Dijkgraaf I, Liu S, Kruijtzer JA, Soede AC, Oyen WJ, Liskamp RM, Corstens FH, Boerman OC.

Nucl Med Biol. 2007 Jan;34(1):29-35.

PMID:
17210459
17.

A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin.

Bleeker-Rovers CP, Vos FJ, Mudde AH, Dofferhoff ASM, de Geus-Oei LF, Rijnders AJ, Krabbe PFM, Corstens FHM, van der Meer JWM, Oyen WJG.

Eur J Nucl Med Mol Imaging. 2007 May;34(5):694-703. doi: 10.1007/s00259-006-0295-z. Epub 2006 Dec 14.

PMID:
17171357
18.

Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists.

Dijkgraaf I, Kruijtzer JA, Frielink C, Soede AC, Hilbers HW, Oyen WJ, Corstens FH, Liskamp RM, Boerman OC.

Nucl Med Biol. 2006 Nov;33(8):953-61.

PMID:
17127167
19.

FDG-PET in colorectal cancer.

de Geus-Oei LF, Ruers TJ, Punt CJ, Leer JW, Corstens FH, Oyen WJ.

Cancer Imaging. 2006 Oct 31;6:S71-81.

20.

Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide.

Dijkgraaf I, Kruijtzer JA, Frielink C, Corstens FH, Oyen WJ, Liskamp RM, Boerman OC.

Int J Cancer. 2007 Feb 1;120(3):605-10.

21.

What is the best pre-therapeutic dosimetry for successful radioiodine therapy of multifocal autonomy?

Gotthardt M, Rubner C, Bauhofer A, Berce F, Oyen WJ, Goecke J, Pfestroff A, Schlieck A, Corstens FH, Béhé M, Behr TM.

Nuklearmedizin. 2006;45(5):206-12.

PMID:
17043731
22.

Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia.

Savonije JH, van Groeningen CJ, van den Broek WJ, Rentinck ME, Corstens FH, Gundy C, Giaccone G, Marx JJ.

Cancer Invest. 2006 Oct;24(6):562-6.

PMID:
16982459
23.

Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250.

Hendrickx BW, Punt CJ, Boerman OC, Postema EJ, Oosterwijk E, Mavridu A, Corstens FH, Oyen WJ.

Cancer Biother Radiopharm. 2006 Jun;21(3):263-8.

PMID:
16918303
24.

Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides.

Dijkgraaf I, Kruijtzer JA, Liu S, Soede AC, Oyen WJ, Corstens FH, Liskamp RM, Boerman OC.

Eur J Nucl Med Mol Imaging. 2007 Feb;34(2):267-73. Epub 2006 Aug 15.

PMID:
16909226
25.

Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody.

van Eerd JE, de Geus-Oei LF, Oyen WJ, Corstens FH, Boerman OC.

Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1266-72. Epub 2006 Jul 11.

PMID:
16832635
26.

Effects of hyperoxygenation on FDG-uptake in head-and-neck cancer.

de Geus-Oei LF, Kaanders JH, Pop LA, Corstens FH, Oyen WJ.

Radiother Oncol. 2006 Jul;80(1):51-6. Epub 2006 Jul 3.

PMID:
16820237
27.

FDG-PET for imaging of non-osseous infection and inflammation.

Vos FJ, Bleeker-Rovers CP, Corstens FH, Kullberg BJ, Oyen WJ.

Q J Nucl Med Mol Imaging. 2006 Jun;50(2):121-30. Review.

28.

Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies.

de Geus-Oei LF, Visser EP, Krabbe PF, van Hoorn BA, Koenders EB, Willemsen AT, Pruim J, Corstens FH, Oyen WJ.

J Nucl Med. 2006 Jun;47(6):945-9.

29.

Decrease of (99m)Tc-uptake in autonomous thyroid tissue in Germany since the 1970s. Clinical implications for radioiodine therapy.

Gotthardt M, Stübinger M, Pansegrau J, Buchwald B, Goecke J, Pfestroff A, Corstens FH, Behr TM.

Nuklearmedizin. 2006;45(3):122-5.

PMID:
16710508
30.

Correction of an image size difference between positron emission tomography (PET) and computed tomography (CT) improves image fusion of dedicated PET and CT.

Vogel WV, van Dalen JA, Schinagl DA, Kaanders JH, Huisman H, Corstens FH, Oyen WJ.

Nucl Med Commun. 2006 Jun;27(6):515-9.

PMID:
16710106
31.

18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results.

de Geus-Oei LF, Pieters GF, Bonenkamp JJ, Mudde AH, Bleeker-Rovers CP, Corstens FH, Oyen WJ.

J Nucl Med. 2006 May;47(5):770-5.

32.

Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats.

van Eerd JE, Vegt E, Wetzels JF, Russel FG, Masereeuw R, Corstens FH, Oyen WJ, Boerman OC.

J Nucl Med. 2006 Mar;47(3):528-33.

33.

Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin.

Vegt E, Wetzels JF, Russel FG, Masereeuw R, Boerman OC, van Eerd JE, Corstens FH, Oyen WJ.

J Nucl Med. 2006 Mar;47(3):432-6.

34.

Colorectal cancer: the role of PET/CT in recurrence.

Vogel WV, Wiering B, Corstens FH, Ruers TJ, Oyen WJ.

Cancer Imaging. 2005 Nov 23;5 Spec No A:S143-9. Review.

35.

18F-FDG PET in detecting metastatic infectious disease.

Bleeker-Rovers CP, Vos FJ, Wanten GJ, van der Meer JW, Corstens FH, Kullberg BJ, Oyen WJ.

J Nucl Med. 2005 Dec;46(12):2014-9.

36.

Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.

Brouwers AH, Buijs WC, Mulders PF, de Mulder PH, van den Broek WJ, Mala C, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7178s-7186s.

37.

Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.

van Schaijk FG, Oosterwijk E, Soede AC, Broekema M, Frielink C, McBride WJ, Goldenberg DM, Corstens FH, Boerman OC.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7130s-7136s.

38.

Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci.

Broekema M, van Eerd JJ, Oyen WJ, Corstens FH, Liskamp RM, Boerman OC, Harris TD.

J Med Chem. 2005 Oct 6;48(20):6442-53.

PMID:
16190770
39.

Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.

Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, Joosten FB, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.

J Clin Oncol. 2005 Sep 20;23(27):6540-8.

PMID:
16170161
40.

Imaging of infection and inflammation with an improved 99mTc-labeled LTB4 antagonist.

van Eerd JE, Broekema M, Harris TD, Edwards DS, Oyen WJ, Corstens FH, Boerman OC.

J Nucl Med. 2005 Sep;46(9):1546-51.

41.

Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection.

Kok PJ, van Eerd JE, Boerman OC, Corstens FH, Oyen WJ.

Cancer Biother Radiopharm. 2005 Jun;20(3):310-5.

PMID:
15989476
42.

Residualizing iodine markedly improved tumor targeting using bispecific antibody-based pretargeting.

van Schaijk FG, Broekema M, Oosterwijk E, van Eerd JE, McBride BJ, Goldenberg DM, Corstens FH, Boerman OC.

J Nucl Med. 2005 Jun;46(6):1016-22.

43.

Comparison of IgG and F(ab')2 fragments of bispecific anti-RCCxanti-DTIn-1 antibody for pretargeting purposes.

van Schaijk FG, Boerman OC, Soede AC, McBride WJ, Goldenberg DM, Corstens FH, Oosterwijk E.

Eur J Nucl Med Mol Imaging. 2005 Sep;32(9):1089-95. Epub 2005 May 18.

PMID:
15902440
44.

Diagnosis of Candida lung abscesses by 18F-fluorodeoxyglucose positron emission tomography.

Bleeker-Rovers CP, Warris A, Drenth JP, Corstens FH, Oyen WJ, Kullberg BJ.

Clin Microbiol Infect. 2005 Jun;11(6):493-5.

45.

Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes.

van Eerd JE, Oyen WJ, Harris TD, Rennen HJ, Edwards DS, Corstens FH, Boerman OC.

J Nucl Med. 2005 May;46(5):786-93.

46.

Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.

van Schaijk FG, Oosterwijk E, Molkenboer-Kuenen JD, Soede AC, McBride BJ, Goldenberg DM, Oyen WJ, Corstens FH, Boerman OC.

J Nucl Med. 2005 Mar;46(3):495-501.

47.

F-18-fluorodeoxyglucose positron emission tomography for visualization of lipodystrophy in HIV-infected patients.

Bleeker-Rovers CP, van der Ven AJ, Zomer B, de Geus-Oei LF, Smits P, Corstens FH, Koopmans PP, Oyen WJ.

AIDS. 2004 Dec 3;18(18):2430-2. No abstract available.

PMID:
15622321
48.

Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut.

de Groot M, Meeuwis AP, Kok PJ, Corstens FH, Oyen WJ.

Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):98-101. Epub 2004 Oct 5.

PMID:
15605289
49.

99mTc-labeled interleukin-8 for scintigraphic detection of pulmonary infections.

Rennen HJ, Bleeker-Rovers CP, van Eerd JE, Frielink C, Oyen WJ, Corstens FH, Boerman OC.

Chest. 2004 Dec;126(6):1954-61.

PMID:
15596698
50.

Discriminating infection from sterile inflammation: can radiolabelled antibiotics solve the problem?

Oyen WJ, Corstens FH, Boerman OC.

Eur J Nucl Med Mol Imaging. 2005 Feb;32(2):151-2. No abstract available.

PMID:
15592927

Supplemental Content

Loading ...
Support Center